Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.
about
High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomasLinkers Having a Crucial Role in Antibody-Drug ConjugatesStrategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer TherapeuticsAdoptive T-cell therapy for LeukemiaThe development of immunoconjugates for targeted cancer therapyA Possible Role for Metallic Ions in the Carbohydrate Cluster Recognition Displayed by a Lewis Y Specific AntibodyGlycoproteins and glycoproteomics in pancreatic cancerTherapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29.Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.Lewisy promotes migration of oral cancer cells by glycosylation of epidermal growth factor receptor.A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinomaIdentification of mRNA splicing factors as the endothelial receptor for carbohydrate-dependent lung colonization of cancer cellsEnhanced immune recognition of cryptic glycan markers in human tumors.Nanotechnology and drug delivery: an update in oncology.Site-specific antibody drug conjugates for cancer therapyChallenges in developing bioanalytical assays for characterization of antibody-drug conjugates.Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.Biosynthetic Machinery Involved in Aberrant Glycosylation: Promising Targets for Developing of Drugs Against CancerTubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.Antibody drug conjugates: lessons from 20 years of clinical experience.Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin.ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates.Probody therapeutics for targeting antibodies to diseased tissue.
P2860
Q21195240-4F871CE9-E03D-45E4-ABEF-7540F75B7EB2Q26752763-1E4140CA-D068-4B31-AD0E-84E1C593F099Q26780335-9BAE58E5-08B2-413D-BF1B-1F72C04636DBQ27006934-B2935CF4-DF49-4837-B75E-A97455A2BD9FQ27021990-00ADE2E1-0697-4111-B35B-3CDD40113D98Q27658123-6DEC5873-A876-47E4-9E5D-8DA6B63725A2Q28071108-0B46A4FE-FF09-4B52-9046-74B51C47CAF1Q34585908-109332D8-03D3-4FCF-9DB6-5B60B28EED0AQ34655256-DDF8B17F-0C48-4EB6-A720-0DBEADF0C40BQ35208732-AC3A9A91-4B12-4761-94EB-BF04368D651EQ37023744-15FE69AE-23E2-4602-999F-F858447C2CD9Q37097214-D81E1017-7094-43B9-8D10-1B1B3ECEC50CQ37133417-213E56EC-702D-4BAD-A657-97D892AE9BAAQ37394893-A6E14F26-74D3-403A-A6AA-71AC94F7DC68Q37593705-297E7A3A-1965-4167-BE93-0BF7F8AFBEC4Q37854644-38265B04-E454-4744-A2C7-33E2E2629E5AQ37962075-F2D4D2D5-098F-428C-8951-19FC254F9104Q38544783-B3E507B4-9444-42E0-99CB-916EE26A70FAQ38648690-01226612-F78B-41CE-B940-56582DA3A81EQ38798481-2FC8651E-2124-476D-BEE1-4D31E1C74973Q38979084-768C4D09-B01A-471A-AA40-264A78F32B47Q43690855-143D97C3-8541-4B06-B399-A5DF364C3CF8Q47197303-B6A1F399-52FD-4035-A42C-63CA05A6B65CQ53546343-5F7BD232-0D5D-4C09-A1C6-02C082C8F1DC
P2860
Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Phase I trial of the anti-Lewi ...... -expressing epithelial tumors.
@ast
Phase I trial of the anti-Lewi ...... -expressing epithelial tumors.
@en
type
label
Phase I trial of the anti-Lewi ...... -expressing epithelial tumors.
@ast
Phase I trial of the anti-Lewi ...... -expressing epithelial tumors.
@en
prefLabel
Phase I trial of the anti-Lewi ...... -expressing epithelial tumors.
@ast
Phase I trial of the anti-Lewi ...... -expressing epithelial tumors.
@en
P2093
P1476
Phase I trial of the anti-Lewi ...... -expressing epithelial tumors.
@en
P2093
A F LoBuglio
C R Daniel
J B Ostroff
P304
P356
10.1200/JCO.2000.18.11.2282
P407
P577
2000-06-01T00:00:00Z